دورية أكاديمية
أعرض في EDS

Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients.

التفاصيل البيبلوغرافية
العنوان: Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients.
المؤلفون: Arfaoui AT; Laboratory of Colorectal Cancer Research UR03ES04, Science University Tunis, Tunis, Tunisia. arfaouiamira@hotmail.com, Kriaa LB, El Hadj Oel A, Ben Hmida MA, Khiari M, Khalfallah T, Gharbi L, Mzabi S, Bouraoui S
المصدر: Virchows Archiv : an international journal of pathology [Virchows Arch] 2010 Sep; Vol. 457 (3), pp. 359-68. Date of Electronic Publication: 2010 Jul 20.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer International, c1994-
مواضيع طبية MeSH: Genetic Predisposition to Disease*, Adenocarcinoma/*genetics , Colorectal Neoplasms/*genetics , DNA-Binding Proteins/*genetics , Nuclear Proteins/*genetics , Polymorphism, Single Nucleotide/*genetics , Tumor Suppressor Proteins/*genetics, Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Case-Control Studies ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Exons ; Female ; Gene Expression Profiling ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Loss of Heterozygosity ; Male ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length ; Retrospective Studies ; Risk Factors ; Tumor Protein p73 ; Tunisia
مستخلص: We examined the association of one linked GC/AT polymorphism at p73 with the risk of colorectal cancer. In the present study, we investigated whether this polymorphism was related to the risk of colorectal cancer, and whether there were relationships between the polymorphism and LOH, protein expression or clinicopathological variables. The p73 genotypes were determined by PCR-restriction fragment length polymorphism in 150 Tunisians patients with colorectal cancer and in 204 healthy control subjects. Immunohistochemistry was performed on normal mucosa, primary tumour and metastasis. The frequencies of the genotypes were 52% for wild-type (GC/GC), 31% for heterozygotes (GC/AT) and 17% for variants (AT/AT) in patients, and 54%, 35% and 11% in controls, respectively. There were no significant differences of the frequencies of the three genotypes between the patients and controls (p = 0.11). We did not find any relationship of the genotypes with clinicopathological features of patients. We found that patients with the AT/AT genotype had a significantly worse clinical outcome than those with the GC/AT and GC/GC genotype. There were no significant differences between tumoural immunostaining of the total p73 and p73 polymorphism (p = 0.16). However, we found a significant difference between the expression profile of DeltaNp73 isoform and frequencies of the three genotypes (p = 0.0001). No LOH was observed at p73 locus. Our results suggest that the AT/AT genotype is significantly associated with poor prognosis in colorectal cancer. All these findings suggest that p73 polymorphism analysis may provide useful prognostic information for colorectal cancer patients.
References: Cancer Res. 2002 Feb 1;62(3):636-41. (PMID: 11830511)
Carcinogenesis. 2004 Oct;25(10):1911-6. (PMID: 15180941)
Hepatology. 2000 Mar;31(3):601-5. (PMID: 10706549)
Br J Cancer. 2001 Nov 16;85(10):1499-503. (PMID: 11720435)
Cancer Res. 2001 Feb 15;61(4):1598-603. (PMID: 11245471)
Nature. 2002 Apr 4;416(6880):560-4. (PMID: 11932750)
Cancer Res. 1998 Jun 1;58(11):2347-9. (PMID: 9622072)
Trends Biochem Sci. 2003 Dec;28(12):663-70. (PMID: 14659698)
Cancer Res. 1999 Jul 1;59(13):3257-63. (PMID: 10397274)
Breast Cancer. 2003;10(4):307-11. (PMID: 14634508)
Oncogene. 1999 Jan 28;18(4):1061-6. (PMID: 10023682)
Oncogene. 1999 Feb 25;18(8):1629-33. (PMID: 10102633)
Clin Cancer Res. 2002 Jan;8(1):165-70. (PMID: 11801554)
Asian Pac J Cancer Prev. 2003 Apr-Jun;4(2):107-12. (PMID: 12875622)
Hum Mutat. 2003 Mar;21(3):182-91. (PMID: 12619104)
Cancer Res. 1998 Apr 1;58(7):1380-3. (PMID: 9537234)
J Biol Chem. 2002 Apr 19;277(16):14177-85. (PMID: 11844800)
Carcinogenesis. 2000 Apr;21(4):683-9. (PMID: 10753204)
Mol Cell Biol. 2003 Aug;23(16):5540-55. (PMID: 12897129)
Nature. 2000 Mar 2;404(6773):99-103. (PMID: 10716451)
Nat Rev Cancer. 2002 Aug;2(8):605-15. (PMID: 12154353)
Mod Pathol. 2001 Apr;14(4):273-8. (PMID: 11301342)
Cancer Res. 1998 May 15;58(10):2076-7. (PMID: 9605745)
Cancer Res. 2004 Oct 1;64(19):6863-6. (PMID: 15466174)
Cell Death Differ. 2001 Dec;8(12):1213-23. (PMID: 11753569)
Cancer Lett. 2004 Mar 8;205(1):55-60. (PMID: 15036661)
Carcinogenesis. 2005 Jan;26(1):103-7. (PMID: 15485994)
J Pathol. 2006 Dec;210(4):385-9. (PMID: 17044134)
Cell. 1997 Aug 22;90(4):809-19. (PMID: 9288759)
Radiother Oncol. 2009 Aug;92(2):215-20. (PMID: 19581013)
Cancer Lett. 2002 Jul 8;181(1):81-5. (PMID: 12430182)
Carcinogenesis. 2007 Feb;28(2):372-7. (PMID: 16950799)
Jpn J Clin Oncol. 2003 May;33(5):215-20. (PMID: 12865464)
Int J Cancer. 1998 Nov 9;78(4):437-40. (PMID: 9797131)
Cell Death Differ. 2007 Feb;14(2):254-65. (PMID: 16645632)
Biochim Biophys Acta. 2001 Dec 28;1552(2):47-59. (PMID: 11825686)
المشرفين على المادة: 0 (DNA-Binding Proteins)
0 (Nuclear Proteins)
0 (TP73 protein, human)
0 (Tumor Protein p73)
0 (Tumor Suppressor Proteins)
0 (delta Np73 protein, human)
تواريخ الأحداث: Date Created: 20100721 Date Completed: 20100928 Latest Revision: 20211020
رمز التحديث: 20221213
DOI: 10.1007/s00428-010-0942-4
PMID: 20644956
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-2307
DOI:10.1007/s00428-010-0942-4